CinCor Pharma, a business that focuses on creating cutting-edge therapies for hypertension and chronic kidney disease, has made arrangements to be acquired by AstraZeneca.

The business will expand AstraZeneca's cardiorenal offering by containing baxdrostat, part of CinCor’s current candidate product portfolio.

“CinCor Pharma has made arrangements to be acquired by AstraZeneca“

Baxdrostat prevents the production of the enzyme aldosterone synthase, meaning one of its functions can be decreasing blood pressure in hypertension resilient with other therapies.

Because it is selective for this particular enzyme and has no effect on the route cortisol takes through the body, the medication may become a pioneering next-generation aldosterone synthase inhibitor.

Additionally, baxdrostat and Farxiga may be used in conjunction, supporting AstraZeneca's objective to deliver positive outcomes for cardiorenal conditions, particularly where a large patient demand has not yet been met.

CEO of CinCor, Marc de Garidel, said that they are “excited about the proposed acquisition of CinCor by AZ as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.”

“CinCor is committed to ensuring a smooth transition of the development responsibilities to AZ a once the acquisition is consummated.”

EVP of BioPharmaceuticals Research & Development at AstraZeneca, Mene Pangalos, expressed that “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat.

“Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.